Florence Healthcare Supports Pfizer’s COVID-19 Vaccine Clinical Trials with Extensive Connectivity Platform
02 September 2020 - 1:30PM
Business Wire
Florence announces collaboration to support
fast-tracked, Phase 2/3 COVID-19 vaccine research
Today, Florence announced a collaboration with Pfizer to support
a global Phase 2/3 COVID-19 vaccine study. Florence is the largest
site and sponsor connectivity platform in the industry, with more
than 7,200 research sites and 18,000 research professionals
leveraging the platform across 27 countries. This extensive network
of connectivity supports the COVID-19 trial by ensuring research
can continue and thrive in a digital capacity, as onsite visits and
collaboration are restricted due to the pandemic.
In addition to a vast network of connectivity, Florence is
uniquely equipped to support the advancement of COVID-19 vaccine
trials due to its advanced suite of products. With support from
Florence’s Remote Site Monitoring Module, coupled with the use of
eBinders, Pfizer was able to accelerate remote site access as it
commenced a global safety and efficacy clinical trial of an
mRNA-based vaccine candidate against SARS-CoV-2 in July 2020.
“We’re very proud to work with Pfizer on this vital trial,” says
Ryan Jones, CEO of Florence. “It’s meaningful work to be able to
support a company that’s at the forefront of innovation for the
benefit of the global community. We will continue our support to
help ensure Pfizer has everything it needs from a clinical trial
software perspective to be successful.”
“Florence’s platform is helping us to respond to the changing
environment due to COVID-19 and further progress COVID-19 research
with the capability to perform remote monitoring where approved by
regulatory authorities and ethics committees,” said Rob Goodwin,
Vice President and Head of the Operations Center of Excellence in
Global Product Development at Pfizer.
POWERED BY FLORENCE
Based in Atlanta, Florence is the leading platform for remote
connectivity and electronic document workflow management in
clinical research and is considered the industry standard with more
than 7,200 research sites in 26 countries, sponsors and CROs
collaborating on its network. Florence advances clinical trials
through software for managing document and data flow between
research sites and sponsors. Florence solutions foster 25% faster
start-up time and 40% reduced document cycle time, among other
benefits. To learn about advancing research through collaboration,
visit www.florencehc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200902005182/en/
Elizabeth Lubben Trevelino/Keller
elubben@trevelinokeller.com